Citations

Clear

4847 citation(s) found for "Tu, Eric".

552: VALPROATE DOSE ASSOCIATED WITH THERAPEUTIC FREE VALPROATE CONCENTRATIONS IN THE CRITICALLY ILL
Webb, Andrew, Riker, Richard, Brown, Caitlin, Lopez, Natasha, Rosenthal, Eric, Zafar, Sahar, Gagnon, David, Rosenthal, Eric S. , Webb, Andrew, Riker, Richard R. , Lopez, Natasha , Gagnon, David J.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001184204.93474.2f Get It

Pediatric Cochlear Implantation for Single-Sided Deafness After Temporal Bone Fracture
Mendenhall, Taylor , Babajanian, Eric E. , Anderson, Cody M. , Pitt, Cache, Tooker, Evan L., Carlson, Matthew L., Patel, Neil S., Espahbodi, Mana , Carlson, Matthew L. , Patel, Neil S. , Gurgel, Richard Klaus

Mayo Clinic

Otology & Neurotology | March 24, 2026 | Volume: 47 | Issue: 5 | Pages: 684-690

10.1097/mao.0000000000004881 | PMID 41872113 Get It

Objective: To examine the benefit of cochlear implantation (CI) in pediatric patients with a history of temporal bone fracture resulting in single-sided deafness (SSD). Study design: Retrospective chart review. Setting: Two tertiary academic centers. Patients: Pediatric patients less than 18 years of age with SSD secondary to temporal bone fracture who underwent CI from 2012 to 2022. Intervention(s): CI. Main outcome measure(s): Postoperative audiometric testing. Results: Seven subjects were identified (median age: 10 years (y); Q1 to Q3: 5 to 16 y). Median time from temporal bone trauma to CI was 7 months (mo) (Q1 to Q3: 3 to 7 mo) and 85% had otic capsule involvement. Subjects were followed for a median length of 12 months (Q1 to Q3: 6 to 24 mo) after CI. All patients achieved full electrode insertion, though 2 required scala vestibuli insertion due to ossification of the scala tympani (one of whom had a history of meningitis after temporal bone fracture). Postoperative audiometric testing revealed variable speech perception outcomes with 4 of 7 obtaining open or closed set speech perception and 3 of 7 obtaining only sound awareness. No postoperative complications occurred. Conclusions: CI is a feasible intervention for SSD following pediatric temporal bone fractures, but outcomes are variable. Early evaluation and timely CI, ideally within 6 months of temporal bone fracture, may optimize outcomes. Cochlear ossification, either as a result of otic capsule fracture or subsequent meningitis, may lead to suboptimal outcomes.
Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study
Sheashaa, Hesham, Ibrahim, Ramzi, Elshaer, Amani , Mouhaffel, Rama, Habib, E., Abdelnabi, Mahmoud, Farina, Juan M., Lester, Steven J., Simper, David, Steidley, Eric, Aqel, B., Barnhill, Michele , Kim, W. Ray, Ayoub, Chadi, Arsanjani, Reza, Ibrahim, Ramzi , Ibrahim, Ramzi , Steidley, Eric D, Pham, Hoang Nhat , Abdelnabi, Mahmoud , Farina, Juan M., Alsidawi, Said , Aqel, Bashar A. , Arsanjani, Reza

Mayo Clinic

Transplantation Direct | March 23, 2026 | Volume: 12 | Issue: 4 | Pages: e1932

10.1097/txd.0000000000001932 | PMID 41884702 Get It

Background. Liver transplant recipients face high risks of cardiometabolic events after transplant, driven by posttransplant weight gain, diabetes, hypertension, as well as immunosuppression-related side effects. Glucagon-like peptide-1 receptor agonists (GLP1RAs) improve metabolic and cardiorenal outcomes in nontransplant populations, but their role in liver transplant recipients remains understudied. Methods. This retrospective cohort study used TriNetX data (January 2010–December 2023) to compare outcomes in liver transplant recipients prescribed GLP1RAs (semaglutide, dulaglutide, liraglutide) within 1-mo posttransplant (n = 546) versus nonusers (n = 37 153). Propensity score matching (1:1) balanced demographics, comorbidities, and medications (n = 541 per group). Outcomes included mortality, hospitalizations, cardiovascular/renal/respiratory events, and graft outcomes. Results. Over a mean follow-up 838.5 d (SD 291.9) in the GLP1RA cohort and 884.3 d (SD 313.7) in the non-GLP1RA group, GLP1RA use was associated with a 43% lower all-cause mortality (7.0% versus 12.9%; hazard ratio [HR], 0.566; 95% confidence interval [CI], 0.381-0.841) and 39% fewer hospitalizations (60.4% versus 74.5%; HR, 0.613; 95% CI, 0.530-0.710). Acute heart failure (HR, 0.386; 95% CI, 0.285-0.524), renal failure/dialysis (HR, 0.489; 95% CI, 0.413-0.579), and respiratory failure (HR, 0.484; 95% CI, 354-0.662) risks were significantly reduced. No differences were observed in graft failure/rejection, myocardial infarction, stroke, atrial fibrillation/flutter, ventricular tachycardia, or ischemic optic neuropathy. Conclusions. Early GLP1RA initiation in liver transplant recipients was associated with reduced mortality, hospitalizations, respiratory, and cardiorenal complications without compromising graft safety. These findings support GLP1RAs as a promising adjunct therapy, warranting prospective trials to confirm benefits in this high-risk population.
Injury Rates and Financial Dollars Lost Due to Injury Continue to Rise in Major League Baseball: An Analysis of Injured List Data Over 15 Seasons From 2010 to 2024
Kang, Louis , Meta, Fabien , Paparesta, Nick, Beacom, Amy S , Bowman, Eric N. , Smith, Matt, Camp, Christopher L. , Kang, Louis S

Mayo Clinic

Arthroscopy | March 20, 2026 | Volume: 42 | Issue: 3 | Pages: 598-609

10.1002/arj.70065 | PMID 41856490 Get It

Purpose To use publicly available injured list (IL) data to 1) describe Major League Baseball injury trends from 2010 to 2024; 2) analyze injury types and body regions affected to report the highest impact injuries; and 3) report the financial implications of time lost due to injury over this 15‐year period. Methods IL data for every Major League Baseball player (pitchers and position players) from the 2010 to 2024 regular seasons were collected using publicly available sources, including player demographics, IL placements, body part injured, and length of each IL stay. Player salaries were compiled to determine the “financial loss” per injury. Results Across 15 seasons, 8078 players were placed on the IL, totaling 478,085 days. The mean IL placements/year was 634, and the annual number increased by an additional 27 injuries/year ( P < .001). Mean total IL days/season was 31,872, and this increased year‐over‐year ( P = .008). Shoulder injuries represented the most IL placements (n = 1555), followed by elbow (n = 1344) and upper leg (n = 769). Elbow injuries averaged the most days missed/IL placement (mean: 93, median: 74) and the greatest total days missed (129,610), followed by shoulder (95,189). Pitchers comprised 55% of IL placements and most commonly injured their shoulder or elbow. Infielders and outfielders accounted for 21% and 16% of IL placements, respectively. A total financial loss of $9,636,753,291 was accumulated over 15 seasons. Financial loss increased season‐to‐season (+$32,309,178/year, P = .002). Elbow injuries accounted for the highest financial loss at $1,932,048,168 ($1,379,049 lost/injury). In 2024, $2,220,432 was lost/elbow injury, $1,110,573/shoulder injury, $1,397,322/any injury, and $952,973,760 total for the season. Conclusions This study observed that the number of players, IL placements, days spent on the IL, and financial loss due to injury increased steadily each year. Pitchers were the most frequently injured players with shoulder and elbow injuries being most common. Over the 15‐season study period, there was a total financial loss of nearly $9.7 billion due to salary paid to injured players, with elbow injuries contributing the highest loss at just under $2 billion. Clinical Relevance Injury trends and financial data from Major League Baseball highlight the growing burden of shoulder and elbow injuries, particularly in pitchers. These findings underscore the need for orthopaedic surgeons to focus on prevention, early intervention, and optimized surgical management of high‐impact injuries to reduce long‐term morbidity and associated financial costs at the elite level.
Deep Learning–based Monoenergetic Imaging for Calcified Coronary Stenosis Assessment at Energy-integrating Detector CT
Chang, Shaojie , Koons, Emily K. , Gong, Hao , Thorne, Jamison E. , Williamson, Eric E. , Foley, Thomas A. , McCollough, Cynthia H., Leng, Shuai, McCollough, Cynthia H. , Leng, Shuai , McCollough, Cynthia H , Leng, Shuai , Williamson, Eric , Thorne, Jamison E , Gong, Hao

Mayo Clinic

Radiology: Cardiothoracic Imaging | March 19, 2026 | Volume: 8 | Issue: 2 | Pages: No page available

10.1148/ryct.250230 | PMID 41854396 Get It

A deep learning–based neural network enabled virtual monoenergetic imaging at energy-integrating detector CT, reduced blooming artifacts, and improved stenosis assessment in heavily calcified coronary plaques, with performance comparable to ultrahigh-resolution photon-counting detector CT.
Gatherings in Esophagology: Innovations and Future Directions in the Diagnosis and Management of Reflux Disease
Cable, Jennifer, Giuli, R, Fox, Mark , Rosen, Rachel L., Valdovinos‐García, Luis R., Siboni, Stefano, Clarke, John O. , Samuels, Tina L. , Scarpignato, Carmelo , Fass, Ronnie, Remes-Troche, José María, Khan, Abraham, Rahman, Afrin Kamal, Lynch, Kristle L. , Jodorkovsky, Daniela , Vela, Marcelo F. , Vandenberg, Alexandra, Kuo, Braden, Ergün, Pelin , Jirapinyo, Pichamol, Asti, Emanuele, Tolone, Salvatore, Salvador, Renato , Sozzi, Marco, Husain, Inna, Wu, J. , Hobson, Anthony, Sharma, Nirmal , Gyawali, C. Prakash, Sifrim, Daniel, Savarino, E V, Bortoli, Nicola De, Rogers, Benjamin D. , Clarke, J , Valdovinos-García, Luis R. , Siboni, Stefano , Johnston, Nikki , Stein, Ellen M. , Fass, Ronnie , Remes Troche, José M , Kuo, Braden , Jirapinyo, Pichamol , Asti, Emanuele , Sheu, Eric Garland , Sozzi, Marco , Hobson, Anthony, Lo, Wai–Kit , Duncan, Daniel R. , Gyawali, C. Prakash , Chan, Walter W. , Sifrim, Daniel

Mayo Clinic

Annals of the New York Academy of Sciences | March 12, 2026 | Volume: 1557 | Issue: 1 | Pages: No page available

10.1111/nyas.70225 | PMID 41817458 Get It

ABSTRACT Recent advances in the diagnosis and management of reflux disease were the central focus of the inaugural Gatherings in Esophagology (GiE), which convened experts across gastroenterology, surgery, otolaryngology, pulmonology, and basic research. The sessions highlighted innovations in reflux monitoring—including high‐resolution manometry, wireless pH monitoring, and novel salivary biomarkers—while critically evaluating their diagnostic accuracy and clinical utility. Presentations explored the limitations of traditional proton‐pump inhibitor therapy, the emergence of potassium‐competitive acid blockers as a new class of acid suppressants, and the evolving role of adjunctive treatments such as mucosal protectants, reflux reducers, and neuromodulators for refractory symptoms. The discourse extended to advanced interventional procedures, including transoral incisionless fundoplication, magnetic sphincter augmentation, and the RefluxStop device, with discussion of patient selection, efficacy, and complication management. Discussants emphasized the pathophysiology and management of extraesophageal manifestations of reflux, the interplay between reflux and pulmonary disease, and the diagnostic challenges in pediatric populations. The meeting also addressed the integration of behavioral therapies, the role of the microbiome, and the application of artificial intelligence in reflux diagnostics. Collectively, these insights underscore a shift toward precision medicine in reflux disease, emphasizing individualized diagnostic strategies and tailored therapeutic approaches to improve patient outcomes.
Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment
Schindler, Suzanne E., Arias, Jalayne J., Beasley, Brent W. , Farrar, Gill , Fowler, Nicole R., Jack, Clifford R., Jönsson, Linus, Joyce, Geoffrey , Lansdall, Claire J., Maruff, Paul, Mattsson‐Carlgren, Niklas, Mummery, Catherine J. , Murphy, Jennifer, Okhravi, Hamid , Petersen, Ronald C., Raman, Rema, Randolph, Christopher , Sass, Marie Reeberg , Reiman, Eric M., Salvadó, Gemma, Schöll, Michael, Siemers, Eric , Sperling, Reisa A., Thornton‐Wells, Tricia, Tortelli, Rosanna , Tosun, Duygu, Vandevrede, Lawren, Weninger, Stacie, Wessels, Alette M. , Zhou, Jin, Carrillo, Marı́a C., Weber, Christopher J., Carrillo, María C. , Jönsson, Linus , Schindler, Suzanne E. , Hansson, Oskar , Algeciras‐Schimnich, Alicia , Arias, Jalayne J. , Fowler, Nicole R. , Hartz, Sarah M. , Jack, Clifford R. , Maruff, Paul , Mattsson, Niklas , Murphy, Jennifer, Petersen, Ronald C. , Raman, Rema , Reiman, Eric M. , Salvadó, Gemma , Sperling, Reisa Anne , Thornton‐Wells, Tricia A., VandeVrede, Lawren , Villain, Nicolas , Zhou, Jin

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | March 12, 2026 | Volume: 12 | Issue: 1 | Pages: No page available

10.1002/trc2.70216 Get It

Abstract Advances in biomarker technology, digital cognitive assessments, and amyloid‐targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer's disease (AD). These advances also create new possibilities for intervention before the onset of cognitive impairment. This paradigm shift has increased the focus on Stages 1 and 2 of AD, in which individuals are cognitively unimpaired but exhibit biological evidence of disease. While early identification of AD offers an opportunity to intervene early to delay progression and preserve quality of life, it also presents complex challenges related to communicating diagnostic results to patients and their families, contextualizing the cost effectiveness of early diagnosis and treatment, and implementation of and equitable access to treatments. Recent, successfully enrolled, preclinical AD trials highlight the complex strategies required to identify asymptomatic, biomarker‐positive individuals on a large scale, and demonstrate critical knowledge gaps in inclusion, follow‐up, and long‐term outcome measurement. The Spring 2025 Alzheimer's Association Research Roundtable (AARR) meeting brought together academics, clinicians, industry, and regulatory leaders to exchange perspectives on current challenges, key learnings, and potential strategies for identifying and treating individuals in very early stages of AD, effectively and safely. This paper presents key takeaways from the Spring 2025 AARR meeting. Highlights New criteria for Alzheimer's disease (AD) enable early identification of AD pathology. Blood tests and digital cognitive assessment tools may facilitate early and personalized care. Plasma biomarkers may be scalable in clinical settings but need confirmation or follow‐up assessments in those individuals with equivocal results. Early therapy shows best results in people with lower initial amyloid and tau burden.
Polymyalgia Rheumatica
Matteson, Eric L., Dejaco, Christian , Matteson, Eric L.

Mayo Clinic

New England Journal of Medicine | March 11, 2026 | Volume: 394 | Issue: 11 | Pages: 1097-1109

10.1056/nejmcp2506817 | PMID 41812194 Get It

AXIN1 Mutated Hepatocellular Carcinoma
Torbenson, Michael, McCabe, Chantal E. , Hohenstein, Jessica D. , O’Brien, Daniel, Chen, Zongming Eric, Wu, Tsung‐Teh, Kakar, Sanjay, Tran, Nguyen H., Wang, Chen, Torbenson, Michael , Kakar, Sanjay , Wang, Chen

Mayo Clinic

American Journal of Surgical Pathology | March 10, 2026 | Volume: 50 | Issue: 6 | Pages: 642-655

10.1097/pas.0000000000002528 | PMID 41804058 Get It

CTNNB1- mutated hepatocellular carcinomas are characterized by a distinctive morphology and activation of the Wnt pathway. AXIN1 also plays a key role in the Wnt pathway, but the morphology of AXIN1-mutated tumors has not been examined. In addition, there are ongoing questions on the ability of AXIN1 mutations to activate the Wnt pathway in hepatocellular carcinoma. AXIN1 mutated tumors (N=18) were studied, along with control groups: CTNNB1 (N=17), APC (6), or “Other” genes in the Wnt pathway (5). Wnt pathway activation was studied by immunostains for beta-catenin and glutamine synthetase. Findings were supplemented by gene expression analysis using TCGA data. On histologic examination, the classic morphology associated with beta-catenin mutations was found in all 4 groups: 8/18 AXIN1 (44%), 10/17 CTNNB1 (59%), 4/6 APC (67%), and 1/5 Other (20%). By immunohistochemistry, Wnt pathway activation was found in 11/18 AXIN1 (61%), 15/17 CTTNB1 (88%), 6/6 APC (100%), and 5/5 (100%) of Other. In AXIN1- mutated tumors, the Wnt pathway was weakly activated. Glutamine synthetase stains also highlighted a new “progressed pattern” associated with distinct subnodules of staining. Tertiary lymphoid structures were uncommon except for cases with CTTNNB1 mutations plus additional mutations in the Wnt pathway. In summary, the classic morphology associated with CTNNB1 mutations is found in hepatocellular carcinomas with mutations in AXIN1 , APC , and other Wnt genes. AXIN1 mutated tumors have Wnt activation that is detectable but at lower levels than CTNNB1 mutated tumors. As tumors progress, their level of Wnt activation can change.